

AtriCure, Inc.  
Form 8-K  
July 09, 2007

---

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

---

### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 5, 2007

---

## AtriCure, Inc.

(Exact name of registrant as specified in charter)

---

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-51470**  
(Commission File Number)

**34-1940305**  
(IRS Employer

Identification No.)

**6033 Schumacher Park Drive**

**West Chester, OH**  
(Address of principal executive offices)

**45069**  
(Zip Code)

Registrant's telephone number, including area code: (513) 755-4100

**Not Applicable**

(Former name or former address, if changed since last report)

---

## Edgar Filing: AtriCure, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On July 5, 2007, our Isolator<sup>®</sup> bipolar ablation clamp system received 510(k) clearance from the Food and Drug Administration, or FDA, for the ablation of cardiac tissue.

A copy of the press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

No.	Description
99.1	Press Release of AtriCure, Inc. dated as of July 9, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRICURE, INC.

By: /s/ Julie A. Piton  
Julie A. Piton  
Vice President and Chief Financial Officer

Dated: July 9, 2007

**EXHIBIT LIST**

<b>No.</b>	<b>Description</b>
99.1	Press Release of AtriCure, Inc. dated as of July 9, 2007.